Huntington’s Disease Gene Therapy: FDA Reversal Delays AMT-130

Key Takeaways

• AMT‑130 cut Huntington’s progression 75% over three years
• FDA reversed stance on external control data usage
• Company plans Type A meeting for accelerated approval pathway
• Therapy seeks approvals in Europe and UK amid US delay

Pulse Analysis

Huntington's disease affects roughly 40,000 Americans, with no disease‑modifying treatments currently approved. AMT‑130 leverages an adeno‑associated virus to deliver a microRNA that silences the mutant huntingtin gene, offering a one‑time, brain‑infused solution. The September 2025 trial, though small, delivered unprecedented efficacy signals, positioning the therapy as a potential first‑in‑class breakthrough in neurodegenerative gene therapy.

The regulatory landscape for novel biologics is evolving, and the FDA's abrupt reversal underscores the tension between innovative trial designs and evidentiary standards. While external control groups like Enroll‑HD provide valuable comparative data when randomized trials are impractical, the agency now questions their robustness for Biologics License Applications. This shift forces sponsors to reconsider data packages, potentially extending development timelines and increasing costs, a trend that could reverberate across the gene‑therapy sector.

Facing the U.S. delay, the company is pivoting to a Type A meeting to negotiate an accelerated approval pathway and is actively engaging European and UK regulators, where acceptance of external controls may be more favorable. Successful approval abroad could generate revenue streams, sustain R&D, and create a precedent for global regulatory harmonization. For investors and patients alike, the outcome will shape market expectations for high‑risk, high‑reward therapies targeting rare, fatal diseases.